Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

epithelial ovarian cancerperitoneal cancerplatinum-resistant ovarian cancerPlatinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Outcome Measures

Primary Outcomes (1)

Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.
Baseline, and every 8 weeks on study

Study Arms (1)

volociximab

EXPERIMENTAL

15 mg/kg volociximab once weekly

Drug: Volociximab

Interventions

VolociximabDrug

15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops

Also known as: M200

volociximab

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information \[PHI\]).
Females aged ≥18 years old at the time of informed consent.

Sponsors & Collaborators

Facet Biotech
Industrylead
Biogen
Industrycollaborator

Study Sites (23)

UCLA JCCC Clinical Research Unit

Los Angeles, California, 90024, United States

UCI Medical Center

Orange, California, 92868-3201, United States

Sharp Hospital

San Diego, California, 92123, United States

Florida Hospital Cancer Institute

Orlando, Florida, 32804, United States

Memorial Health University Medical Center

Savannah, Georgia, 31404, United States

University of Chicago

Chicago, Illinois, 60637, United States

Indiana University

Indianapolis, Indiana, 46202, United States

MeSH Terms

Conditions

Ovarian NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial

Interventions

volociximab

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, Female

Study Officials

Carolyn Matthews, MD
Mary Crowley Medical Research Center
PRINCIPAL INVESTIGATOR
Minal Barve, MD
Texas Oncology PA, Presbyterian
PRINCIPAL INVESTIGATOR
James Burke, MD
Billings Clinic (MCMRC network)
PRINCIPAL INVESTIGATOR
Dana Glenn, MD
Sharp Hospital
PRINCIPAL INVESTIGATOR

Enrollment

16 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 14, 2007

First Posted

August 16, 2007

Study Start

August 2007

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

volociximab

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (23)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

volociximab

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (23)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations